Kaufmann Robert, Harris Bozer Amber, Jotte Amanda Rose Kube, Aqua Keith
Midwest Allergy Sinus Asthma PC, Springfield, IL, USA.
Tarleton State University, Stephenville, TX, USA.
Med Cannabis Cannabinoids. 2023 Mar 22;6(1):32-40. doi: 10.1159/000529677. eCollection 2023 Jan-Dec.
Previous research indicated that cannabidiol (CBD) may result in low levels of male total testosterone (TT), elevations in liver tests (LTs), and daytime drowsiness (DD). We investigated the prevalences of TT and LT in a large adult sample self-administering CBD and determined the effect self-dosing of CBD has on the severity of DD.
Adult participants (18-75 years of age) who self-dose CBD orally for a minimum of 30 days were recruited for this decentralized observational study from companies that offer CBD products. Participants were sent their usual CBD regimen. A clinical study platform was used on a phone app to obtain consent and collect study data. Data included demographic information, reasons for self-dosing, dosage, current medications and dosage, medical history, adverse effects, effects on DD, and efficacy. After 30 days, LT and TT were obtained and follow-up LT was offered to participants who demonstrated elevated values of alanine transaminase (ALT).
A total of 28,121 individuals were contacted, 1,475 met the criteria and were enrolled, and 1,061 (female: 65.2%, male: 34.8%) completed the study. Most of the participants used full-spectrum CBD oil or CBD isolate with the mean ± SD daily dose of CBD for all users of 55.4 ± 37.8 mg. CBD use was associated with a significant decrease in DD and a decrease in the prevalence of low TT in males >40 years of age. The prevalences of elevations in ALT and aspartate aminotransferase were not significantly different from those of the general adult population, and the prevalences of elevated levels of alkaline phosphatase and bilirubin were less than those of a healthy adult population. There was no relationship between LT and CBD dose.
In this large-sample study, self-dosing CBD was not associated with an increased prevalence of elevation of LT or low levels of TT in men. Furthermore, CBD administration decreased DD and was associated with a lower prevalence of low testosterone levels in older men as compared to age-adjusted population norms.
先前的研究表明,大麻二酚(CBD)可能会导致男性总睾酮(TT)水平降低、肝功能检查(LTs)指标升高以及日间嗜睡(DD)。我们调查了大量自行服用CBD的成年样本中TT和LT的患病率,并确定了CBD自行给药对DD严重程度的影响。
从提供CBD产品的公司招募了口服自行给药CBD至少30天的成年参与者(18 - 75岁)参与这项分散式观察性研究。向参与者发送他们常用的CBD治疗方案。使用手机应用上的临床研究平台来获取同意并收集研究数据。数据包括人口统计学信息、自行给药的原因、剂量、当前用药及剂量、病史、不良反应、对DD的影响以及疗效。30天后,获取LT和TT数据,并为丙氨酸转氨酶(ALT)值升高的参与者提供后续的LT检测。
总共联系了28121人,1475人符合标准并被纳入研究,1061人(女性:65.2%,男性:34.8%)完成了研究。大多数参与者使用全谱CBD油或CBD分离物,所有使用者的CBD平均每日剂量±标准差为55.4±37.8毫克。使用CBD与DD显著降低以及40岁以上男性低TT患病率降低相关。ALT和天冬氨酸转氨酶升高的患病率与一般成年人群无显著差异,碱性磷酸酶和胆红素水平升高的患病率低于健康成年人群。LT与CBD剂量之间没有关系。
在这项大样本研究中,自行服用CBD与男性LT升高或TT水平降低的患病率增加无关。此外,与年龄调整后的人群标准相比,服用CBD可降低DD,并与老年男性低睾酮水平的较低患病率相关。